Education
About Us
Working with TipRanks
Follow Us
Hims & Hers Health (DE:82W)
FRANKFURT:82W
82W Stock Chart & Stats
€21.75
-€0.66(-2.50%)
At close: 4:00 PM EST
€21.75
-€0.66(-2.50%)
Day’s Range― - ―
52-Week Range€11.82 - €61.70
Previous CloseN/A
Volume1.67K
Average Volume (3M)3.85K
Market Cap
$4.93B
Enterprise Value€6.50B
Total Cash (Recent Filing)$577.49M
Total Debt (Recent Filing)$1.26B
Price to Earnings (P/E)56.9
Beta1.62
Next Earnings
May 11, 2026EPS Estimate
<0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.07
Shares Outstanding219,561,140
10 Day Avg. Volume4,120
30 Day Avg. Volume3,853
Financial Highlights & Ratios
PEG Ratio-33.00
Price to Book (P/B)13.50
Price to Sales (P/S)3.11
P/FCF Ratio98.76
Enterprise Value/Market Cap1.32
Enterprise Value/Revenue2.77
Enterprise Value/Gross Profit3.97
Enterprise Value/Ebitda38.29
Forecast
1Y Price Target
$22.71Price Target Upside4.41% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering14
EPS Forecast (FY)0.45
Revenue Forecast (FY)$2.39B
Bulls Say, Bears Say
Bulls Say
Legal And Regulatory Risk ReductionThe dismissal of litigation with Novo Nordisk and the renewed distribution agreement remove a major legal overhang for Hims & Hers Health, lowering litigation and enforcement risk and supporting improved investor confidence.
Partnership-driven Revenue UpsidePotential revenue-sharing arrangements and additional partnerships with pharmaceutical manufacturers create upside to revenue by enabling premium-priced branded weight-loss offerings and better retention of GLP-1 members.
Product Assortment And CompetitivenessAbility to offer branded GLP-1 medicines and bundles that include provider access and wellness guidance expands Hims & Hers Health's weight-loss product assortment and helps the company remain competitive on its telehealth platform.
Bears Say
Execution Risk To Replace Lost Compounding RevenueReplacing revenue lost from discontinuing mass-compounded GLP-1 offerings would require a very large increase in subscription sales, increasing execution risk and making outlook dependent on substantial member growth and retention.
Margin Pressure From Branded DrugsBranded GLP-1 prescriptions are expected to generate lower profit per prescription than prior compounded treatments, creating margin pressure and potential declines in adjusted EBITDA unless offset by higher volumes or pricing.
Revenue Recognition And Reported Sales ImpactShifting to a model that records only Hims & Hers Health's share of branded transactions could materially reduce reported revenue if subscribers move from gross-recognized compounded treatments to branded prescriptions.
Hims & Hers Health News
82W FAQ
What was Hims & Hers Health’s price range in the past 12 months?
Hims & Hers Health lowest stock price was €11.81 and its highest was €61.70 in the past 12 months.
What is Hims & Hers Health’s market cap?
Hims & Hers Health’s market cap is $4.93B.
When is Hims & Hers Health’s upcoming earnings report date?
Hims & Hers Health’s upcoming earnings report date is May 11, 2026 which is in 54 days.
How were Hims & Hers Health’s earnings last quarter?
Hims & Hers Health released its earnings results on Feb 23, 2026. The company reported €0.069 earnings per share for the quarter, beating the consensus estimate of €0.034 by €0.034.
Is Hims & Hers Health overvalued?
According to Wall Street analysts Hims & Hers Health’s price is currently Undervalued.
Does Hims & Hers Health pay dividends?
Hims & Hers Health does not currently pay dividends.
What is Hims & Hers Health’s EPS estimate?
Hims & Hers Health’s EPS estimate is <0.01.
How many shares outstanding does Hims & Hers Health have?
Hims & Hers Health has 219,561,140 shares outstanding.
What happened to Hims & Hers Health’s price movement after its last earnings report?
Hims & Hers Health reported an EPS of €0.069 in its last earnings report, beating expectations of €0.034. Following the earnings report the stock price went up 1.527%.
Which hedge fund is a major shareholder of Hims & Hers Health?
Currently, no hedge funds are holding shares in DE:82W
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Hims & Hers Health Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$22.71 (4.41% Upside)
$22.71 (4.41% Upside)
Blogger Sentiment
Bullish
DE:82W Sentiment 85%
Sector Average 70%
Sector Average 70%
Insider Transactions
Sold Shares
Worth $414.2K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 90%
Bearish news 10%
Bearish news 10%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-21.46%
12-Months-Change
Fundamentals
Return on Equity
22.99%
Trailing 12-Months
Asset Growth
197.28%
Trailing 12-Months
Company Description
Hims & Hers Health
Hims & Hers Health, Inc. operates a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals. The company offers a range of health and wellness products and services available to purchase on its websites and mobile application directly by customers. It also provides prescription medication on a recurring basis and ongoing care from healthcare providers; and over-the-counter drug and device products, cosmetics, and supplement products, primarily focusing on wellness, sexual health and wellness, skincare, and hair care. The company's curated non-prescription products include vitamin C, melatonin, biotin, and collagen protein supplements in the wellness category; moisturizer, serums, and face wash in the skincare category; condoms, climax delay spray and wipes, vibrators, and lubricants in the sexual health and wellness category; and shampoos, conditioners, scalp scrubs, and topical treatments, such as minoxidil in the hair care category. In addition, it offers medical consultation services, as well as health and wellness products through wholesale partners. The company is based in San Francisco, California.
82W Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong commercial momentum and financial improvement: robust top-line growth (Q4 +28%, FY +59%), expanding profitability (adjusted EBITDA +~80%), growing subscriber base (>2.5M) and meaningful cash generation. Management emphasized rapid product launches, diagnostic and hormonal early successes, and aggressive international expansion via acquisitions. Offsetting these positives are near-term headwinds from fulfillment timing ($65M Q1 revenue timing impact), margin pressure from investments and international mix, regulatory uncertainty around compounded GLP-1s, and sizable acquisition-related commitments. Overall, fundamentals and strategic investments appear to outweigh the near-term risks, though execution and regulatory outcomes will be key to sustaining the trajectory.View all DE:82W earnings summaries82W Revenue Breakdown
96.60% Online
3.40% Wholesale
82W Stock 12 Month Forecast
Average Price Target
€22.71
▲(4.41% Upside)
Technical Analysis
Options Prices
Currently, No data available
---